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Dr. Russell raises important points regarding the diagnostic
criteria for chronic migraine (CM) and medication overuse
headache (MOH). We agree that the deﬁnitions for these
entities have posed challenges for the past two decades.
The ICHD-2 diagnostic criteria for CM and MOH were
evolving as the PREEMPT clinical trial program was
developed and launched. In the original ICHD-2 deﬁnition
of MOH, remission of headache[15 days per month fol-
lowing discontinuation of medication was required. As a
consequence, the diagnosis could be assigned only to
individuals who no longer had the condition. The ICHD-2R
deﬁnition of MOH no longer requires remission after
withdrawal [1]. A history of headache escalation during a
period of medication overuse is still required by ICHD-2R,
though in the vast majority of patients it is not possible to
reliably determine if medication overuse is a cause or a
consequence of increasing headache frequency. Moreover,
contrary to conventional wisdom, there is no evidence from
controlled trials that the withdrawal of acute medications
alone, in those who ‘‘overuse’’ them, leads to the long-term
remission of headache.
In the PREEMPT program, patients who otherwise met
study criteria for CM were not excluded if they were
making frequent use of acute medication. Contrary to
Dr. Russell’s assertion, additional data are needed to
determine which of these patients meet criteria for MOH.
The decision not to exclude patients overusing acute
medication was made based on consultation with members
of the Task Force of the International Headache Society
Clinical Trials Subcommittee, and is consistent with their
published guidelines for controlled trials of prophylactic
treatment of CM in adults [2]. These guidelines reﬂect the
high prevalence of medication overuse in CM patients, and
recommend the inclusion and stratiﬁcation of these patients
in clinical studies. In line with these guidelines, patients
with medication overuse were stratiﬁed at randomization in
the PREEMPT clinical program [3]. If patients with med-
ication overuse are excluded, we lose the opportunity to
address the beneﬁts of treatment in a large group with
disabling headache and an unmet treatment need. Results
from an independent clinic-based study designed to assess
the overlap between ICHD-2R and other proposed diag-
nostic criteria for CM (including PREEMPT enrollment
criteria) determined that there was signiﬁcant overlap
between these deﬁnitions [4].
We completely agree with Dr. Russell that subgroup
analyses are warranted. Data have been presented on the
medication overuse subpopulation demonstrating efﬁcacy
of onabotulinumtoxinA compared to placebo on multiple
headache symptom measures [5], and a manuscript is in
progress. Additional post hoc analysis of subgroup popu-
lations, such as those PREEMPT patients who have taken
prior prophylaxis, are currently underway and will also be
detailed in future publications.
We believe the PREEMPT study enrolled patients rep-
resentative of the CM population and that the results of the
program have greater generalizability because of our
inclusion criteria. These studies show that onabotulinum-
toxinA treatment compared to placebo resulted in clinically
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quency; and signiﬁcantly improved functioning, vitality,
and overall quality of life [3]. As clinicians dedicated to the
care of patients with headache, identiﬁcation and success-
ful prophylactic treatment of this highly disabled patient
population is our main objective.
Sincerely,
Sheena Aurora, MD
Hans-Christoph Diener, MD
David Dodick, MD
On behalf of the PREEMPT Chronic Migraine Study
Group
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